Azapirona (Portuguese Wikipedia)
Analysis of information sources in references of the Wikipedia article "Azapirona" in Portuguese language version.
refsWebsite
Global rank
Portuguese rank
1st place
1st place
doi.org
dx.doi.org
- Eison AS. «Azapirones: history of development». Journal of Clinical Psychopharmacology. 10: 2S–5S. PMID 1973936. doi:10.1097/00004714-199006001-00002
- «Azapirones for generalized anxiety disorder». Cochrane Database of Systematic Reviews. 3: CD006115. 2006. PMID 16856115. doi:10.1002/14651858.CD006115
- Feighner JP, Boyer WF (1989). «Serotonin-1A anxiolytics: an overview». Psychopathology. 22 Suppl 1: 21–6. PMID 2567039. doi:10.1159/000284623
- «Pharmacological treatment of social anxiety disorder». Anxiety Disorders. Col: Modern Trends in Pharmacopsychiatry. 29. [S.l.: s.n.] 2013. pp. 144–53. ISBN 978-3-318-02463-0. PMID 25225024. doi:10.1159/000351960
- Van Ameringen M, Mancini C, Wilson C. «Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia». Journal of Affective Disorders. 39: 115–21. PMID 8827420. doi:10.1016/0165-0327(96)00030-4
- Dimitriou EC, Dimitriou CE. «Buspirone augmentation of antidepressant therapy». Journal of Clinical Psychopharmacology. 18: 465–9. PMID 9864079. doi:10.1097/00004714-199812000-00009
- Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. «Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study». The Journal of Clinical Psychiatry. 62: 448–52. PMID 11465522. doi:10.4088/JCP.v62n0608
- Yamada K, Yagi G, Kanba S. «Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial». Psychiatry and Clinical Neurosciences. 57: 183–7. PMID 12667165. doi:10.1046/j.1440-1819.2003.01099.x
- et al. (2006). «Azapirones for generalized anxiety disorder.». Reviews: CD006115. PMID 16856115. doi:10.1002/14651858.CD006115
- «Pharmacological treatment of social anxiety disorder». Anxiety Disorders. Col: Modern Trends in Pharmacopsychiatry. 29. [S.l.: s.n.] 20 de setembro de 2013. pp. 144–53. ISBN 978-3-318-02463-0. PMID 25225024. doi:10.1159/000351960
- «Serotonergic drugs for depression and beyond». Curr Drug Targets. 14: 578–85. PMID 23531115. doi:10.2174/1389450111314050007
- «Azapirones versus placebo for panic disorder in adults». The Cochrane Database of Systematic Reviews. 9: CD010828. PMID 25268297. doi:10.1002/14651858.CD010828.pub2
- Grover M, Camilleri M. «Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases». J Gastroenterol. 48: 177–81. PMC 3698430
. PMID 23254779. doi:10.1007/s00535-012-0726-5 - Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ. «Review of the side-effect profile of buspirone». The American Journal of Medicine. 80: 17–21. PMID 2870641. doi:10.1016/0002-9343(86)90327-X
- Davidson JR, Feltner DE, Dugar A. «Management of Generalized Anxiety Disorder in Primary Care: Identifying the Challenges and Unmet Needs». Prim Care Companion J Clin Psychiatry. 12. PMC 2911006. PMID 20694114. doi:10.4088/PCC.09r00772blu
- et al. «Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment». The American Journal of Psychiatry. 158: 1722–5. PMID 11579010. doi:10.1176/appi.ajp.158.10.1722
- Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. «Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study». Schizophrenia Research. 95: 158–68. PMID 17628435. doi:10.1016/j.schres.2007.06.008
- Piskulić D, Olver JS, Maruff P, Norman TR. «Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist». Human Psychopharmacology. 24: 437–46. PMID 19637398. doi:10.1002/hup.1046
nih.gov
ncbi.nlm.nih.gov
- Eison AS. «Azapirones: history of development». Journal of Clinical Psychopharmacology. 10: 2S–5S. PMID 1973936. doi:10.1097/00004714-199006001-00002
- Cadieux RJ. «Azapirones: an alternative to benzodiazepines for anxiety». American Family Physician. 53: 2349–53. PMID 8638511
- «Azapirones for generalized anxiety disorder». Cochrane Database of Systematic Reviews. 3: CD006115. 2006. PMID 16856115. doi:10.1002/14651858.CD006115
- Feighner JP, Boyer WF (1989). «Serotonin-1A anxiolytics: an overview». Psychopathology. 22 Suppl 1: 21–6. PMID 2567039. doi:10.1159/000284623
- «Pharmacological treatment of social anxiety disorder». Anxiety Disorders. Col: Modern Trends in Pharmacopsychiatry. 29. [S.l.: s.n.] 2013. pp. 144–53. ISBN 978-3-318-02463-0. PMID 25225024. doi:10.1159/000351960
- Van Ameringen M, Mancini C, Wilson C. «Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia». Journal of Affective Disorders. 39: 115–21. PMID 8827420. doi:10.1016/0165-0327(96)00030-4
- Bouwer C, Stein DJ. «Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression». South African Medical Journal. 87: 534–7, 540. PMID 9180827
- Dimitriou EC, Dimitriou CE. «Buspirone augmentation of antidepressant therapy». Journal of Clinical Psychopharmacology. 18: 465–9. PMID 9864079. doi:10.1097/00004714-199812000-00009
- Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. «Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study». The Journal of Clinical Psychiatry. 62: 448–52. PMID 11465522. doi:10.4088/JCP.v62n0608
- Yamada K, Yagi G, Kanba S. «Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial». Psychiatry and Clinical Neurosciences. 57: 183–7. PMID 12667165. doi:10.1046/j.1440-1819.2003.01099.x
- et al. (2006). «Azapirones for generalized anxiety disorder.». Reviews: CD006115. PMID 16856115. doi:10.1002/14651858.CD006115
- «Pharmacological treatment of social anxiety disorder». Anxiety Disorders. Col: Modern Trends in Pharmacopsychiatry. 29. [S.l.: s.n.] 20 de setembro de 2013. pp. 144–53. ISBN 978-3-318-02463-0. PMID 25225024. doi:10.1159/000351960
- «Serotonergic drugs for depression and beyond». Curr Drug Targets. 14: 578–85. PMID 23531115. doi:10.2174/1389450111314050007
- «Azapirones versus placebo for panic disorder in adults». The Cochrane Database of Systematic Reviews. 9: CD010828. PMID 25268297. doi:10.1002/14651858.CD010828.pub2
- Grover M, Camilleri M. «Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases». J Gastroenterol. 48: 177–81. PMC 3698430. PMID 23254779. doi:10.1007/s00535-012-0726-5
- Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ. «Review of the side-effect profile of buspirone». The American Journal of Medicine. 80: 17–21. PMID 2870641. doi:10.1016/0002-9343(86)90327-X
- Davidson JR, Feltner DE, Dugar A. «Management of Generalized Anxiety Disorder in Primary Care: Identifying the Challenges and Unmet Needs». Prim Care Companion J Clin Psychiatry. 12. PMC 2911006. PMID 20694114. doi:10.4088/PCC.09r00772blu
- et al. «Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment». The American Journal of Psychiatry. 158: 1722–5. PMID 11579010. doi:10.1176/appi.ajp.158.10.1722
- Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. «Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study». Schizophrenia Research. 95: 158–68. PMID 17628435. doi:10.1016/j.schres.2007.06.008
- Piskulić D, Olver JS, Maruff P, Norman TR. «Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist». Human Psychopharmacology. 24: 437–46. PMID 19637398. doi:10.1002/hup.1046
web.archive.org
- «The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances» (PDF). 2004. Consultado em 1 de março de 2010. Cópia arquivada (PDF) em 22 de julho de 2011
who.int
apps.who.int
libdoc.who.int
- «The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances» (PDF). 2004. Consultado em 1 de março de 2010. Cópia arquivada (PDF) em 22 de julho de 2011